Importantly, the combination with venetoclax had an apparent synergistic effect on DNA damage that in turn reduced the expression of MCL‐1 protein leading to a significant enhancement of antitumor potency in AML cell lines resistant to single‐agent venetoclax. Here, MCL1 is linked to acute myeloid leukemia.